keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy inducing anemia

keyword
https://www.readbyqxmd.com/read/28504901/tale-of-two-erythropoiesis-stimulating-agents-utilization-dosing-litigation-and-costs-of-darbepoetin-and-epoetin-among-south-carolina-medicaid-covered-patients-with-cancer-and-chemotherapy-induced-anemia
#1
Virginia Noxon, Kevin B Knopf, LeAnn B Norris, Brian Chen, Y Tony Yang, Zaina P Qureshi, William Hrushesky, Akida A Lebby, Benjamin Schooley, Neset Hikmet, Michael Dickson, Mae Thamer, Dennis Cotter, Paul R Yarnold, Charles L Bennett
PURPOSE: The US Food and Drug Administration (FDA) has approved epoetin and darbepoetin for chemotherapy-induced anemia (CIA). Approved epoetin and darbepoetin dosing schedules were three times per week and weekly, respectively, although off-label, less frequent scheduling was common. In 2004, 2007, and 2008, a US Food and Drug Administration Advisory Committees warned of risks associated with erythropoiesis-stimulating agents. During this period, lawsuits alleging illegal darbepoetin marketing practices have concluded, resulting in $1...
May 15, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28448368/managing-chemotherapy-induced-anemia-with-erythropoiesis-stimulating-agents-plus-iron
#2
REVIEW
Lisa Whitehead
Editor's note: This is a summary of a nursing care-related systematic review from the Cochrane Library.
May 2017: American Journal of Nursing
https://www.readbyqxmd.com/read/28441110/effects-of-the-us-food-and-drug-administration-boxed-warning-of-erythropoietin-stimulating-agents-on-utilization-and-adverse-outcome
#3
John Bian, Brian Chen, Dawn L Hershman, Norman Marks, LeAnn Norris, Richard Schulz, Charles L Bennett
Purpose In March 2007, a US Food and Drug Administration boxed warning was issued for erythropoietin-stimulating agents (ESAs) regarding serious adverse events, such as venous thromboembolism (VTE). We evaluated the US Food and Drug Administration's boxed warning of ESAs used to treat chemotherapy-induced anemia because evidence on the effectiveness of boxed warnings remains inconclusive. Patients and Methods Using 2004 to 2009 SEER-Medicare data, we exploited a natural experiment to examine the effects of ESA boxed warnings on utilization and risk of VTE...
April 25, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28397504/-chemotherapy-related-cognitive-impairment-in-patients-with-hodgkin-lymphoma-pathophysiology-and-risk-factors
#4
D Fayette, Ľ Gahérová, H Móciková, J Marková, T Kozák, J Horáček
BACKGROUND: Cognitive impairment (impairment of memory, attention, or concentration) is documented in 17-75% of patients with various malignancies treated with chemotherapeutic agents that worsen quality of life. CRCI affects patients of all ages. The impairment of cognitive function in connection with chemotherapy is usually mild, but an event. relationship with dementia remains to be confirmed. Chemotherapy in combination with radiotherapy in Hodgkin lymphoma can cure 80-90% of patients...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/28391437/oral-sucrosomial-iron-versus-intravenous-iron-in-anemic-cancer-patients-without-iron-deficiency-receiving-darbepoetin-alfa-a-pilot-study
#5
Antonino Mafodda, D Giuffrida, A Prestifilippo, D Azzarello, R Giannicola, M Mare, R Maisano
PURPOSE: Erythropoiesis-stimulating agents (ESAs) are often used in treatment of patients with chemotherapy-induced anemia. Many studies have demonstrated an improved hemoglobin (Hb) response when ESA is combined with intravenous iron supplementation and a higher effectiveness of intravenous iron over traditional oral iron formulations. A new formulation of oral sucrosomial iron featuring an increased bioavailability compared to traditional oral formulations has recently become available and could provide a valid alternative to those by intravenous (IV) route...
April 9, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28377717/biomarkers-associated-with-cognitive-impairment-in-treated-cancer-patients-potential-predisposition-and-risk-factors
#6
REVIEW
Hélène Castel, Angeline Denouel, Marie Lange, Marie-Christine Tonon, Martine Dubois, Florence Joly
Purpose: Cognitive impairment in cancer patients induced, at least in part, by treatment are frequently observed and likely have negative impacts on patient quality of life. Such cognitive dysfunctions can affect attention, executive functions, and memory and processing speed, can persist after treatment, and their exact causes remain unclear. The aim of this review was to create an inventory and analysis of clinical studies evaluating biological markers and risk factors for cognitive decline in cancer patients before, during, or after therapy...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28371203/the-available-intravenous-iron-formulations-history-efficacy-and-toxicology
#7
REVIEW
Michael Auerbach, Iain Macdougall
A number of intravenous iron formulations have been developed over the past 65 years which rely on dextran or other compounds to prevent uncontrolled release of free iron to the circulation. High molecular weight dextran was associated with a number of serious adverse reactions and was removed from markets worldwide in 2009. The preponderance of published evidence suggests that the formulations of parenteral iron currently available in the United States, including low molecular weight iron dextran, are all safe and effective and there are no major, clinically important differences among them in terms of either efficacy or safety...
June 2017: Hemodialysis International
https://www.readbyqxmd.com/read/28359342/measuring-the-impact-of-ambulatory-red-blood-cell-transfusion-on-home-functional-status-study-protocol-for-a-pilot-randomized-controlled-trial
#8
Dennis H Murphree, Theresa N Kinard, Nandita Khera, Curtis B Storlie, Che Ngufor, Sudhindra Upadhyaya, Jyotishman Pathak, Emma Fortune, Eapen K Jacob, Rickey E Carter, Karl A Poterack, Daryl J Kor
BACKGROUND: Red blood cell (RBC) transfusion is frequently employed in both ambulatory and hospital environments with the aim of improving patient functional status. In the ambulatory setting, this practice is particularly common in patients with malignancy due to anemia associated with their cancer therapy. Increasingly, the efficacy of this US$10.5 billion per year practice has been called into question. While it is often standard of care for patients with chemotherapy-induced anemia to receive ambulatory RBC transfusions, it is unclear to what extent such transfusions affect home functional status...
March 31, 2017: Trials
https://www.readbyqxmd.com/read/28358695/induction-of-tgf-%C3%AE-by-irradiation-or-chemotherapy-in-fanconi-anemia-fa-mouse-bone-marrow-is-modulated-by-small-molecule-radiation-mitigators-jp4-039-and-mms350
#9
Michael W Epperly, Byung-Han Rhieu, Darcy Franicola, Tracy Dixon, Shaonan Cao, Xichen Zhang, Donna Shields, Hong Wang, Peter Wipf, Joel S Greenberger
BACKGROUND/AIM: Total-body irradiation and/or administration of chemotherapy drugs in bone marrow transplantation induce cytokines that can suppress engraftment. Fanconi Anemia (FA) patients have a hyperactive responsiveness to the inhibitory cytokine, transforming growth factor-beta (TGF-β). Small molecule radiation mitigator drugs, JP4-039 and MMS350, were evaluated for suppression of irradiation or drug-induced TGF-β. MATERIALS AND METHODS: In vivo induction of TGF-β by total-body ionizing irradiation (TBI), L-phenylalanine mustard (L-PAM), busulfan or fludarabine, was quantified...
March 2017: In Vivo
https://www.readbyqxmd.com/read/28315701/perspective-a-defined-role-for-multiple-fanconi-anemia-gene-products-in-dna-damage-associated-ubiquitination
#10
REVIEW
Winnie Tan, Andrew J Deans
Fanconi anemia (FA) is an inherited blood disorder that causes bone marrow failure and high predisposition to cancers. The FA pathway guards the cell's genome stability by orchestrating the repair of interstrand cross-linking during the S phase of the cell cycle, preventing the chromosomal instability that is a key event in bone marrow failure syndrome. Central to the FA pathway is loss of monoubiquitinated forms of the Fanconi proteins FANCI and FANCD2, a process that is normally mediated by a "core complex" of seven other Fanconi proteins...
March 16, 2017: Experimental Hematology
https://www.readbyqxmd.com/read/28280364/biosimilar-retacrit-%C3%A2-epoetin-zeta-in-the-treatment-of-chemotherapy-induced-symptomatic-anemia-in-hematology-and-oncology-in-germany-orheo-non-interventional-study
#11
Christoph Losem, Michael Koenigsmann, Christine Rudolph
BACKGROUND: Symptomatic anemia is a frequent and severe complication of chemotherapy that is commonly treated with erythropoiesis-stimulating agents. The primary objective of this study was to assess the change in hemoglobin levels in patients with chemotherapy-induced anemia (CIA) following treatment with biosimilar Retacrit(®) (epoetin zeta). Secondary objectives included changes in hematologic parameters and tolerability. METHODS: This was a non-interventional, multicenter, long-term observational study that is part of an ongoing surveillance program for epoetin zeta...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28247960/erythropoietin-induces-an-epithelial-to-mesenchymal-transition-like-process-in-mammary-epithelial-cells-mcf10a
#12
Alejandra Ordoñez-Moreno, Cecilia Rodriguez-Monterrosas, Pedro Cortes-Reynosa, Julio Isael Perez-Carreon, Eduardo Perez Salazar
Anemia is associated with chemotherapy treatment in cancer patients. Erythropoietin (EPO) has been used to treat anemia of cancer patients, because it stimulates erythropoiesis. However, treatment of breast cancer patients with EPO has been associated with poor prognosis and decrease of survival. Epithelial to mesenchymal transition (EMT) is a process by which epithelial cells are transdifferentiated to a mesenchymal state. It has been implicated in tumor progression, because epithelial cells acquire the capacity to execute the multiple steps of invasion/metastasis process...
March 1, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28167659/targeting-bruton-tyrosine-kinase-with-ibrutinib-in-relapsed-refractory-marginal-zone-lymphoma
#13
Ariela Noy, Sven de Vos, Catherine Thieblemont, Peter Martin, Christopher R Flowers, Franck Morschhauser, Graham P Collins, Shuo Ma, Morton Coleman, Shachar Peles, Stephen Smith, Jacqueline C Barrientos, Alina Smith, Brian Munneke, Isaiah Dimery, Darrin M Beaupre, Robert Chen
Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no standard treatment exists. MZL is frequently linked to chronic infection, which may induce B-cell receptor (BCR) signaling, resulting in aberrant B-cell survival and proliferation. We conducted a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of ibrutinib in previously treated MZL. Patients with histologically confirmed MZL of all subtypes who received ≥1 prior therapy with an anti-CD20 antibody-containing regimen were treated with 560 mg ibrutinib orally once daily until progression or unacceptable toxicity...
April 20, 2017: Blood
https://www.readbyqxmd.com/read/28078434/a-retrospective-open-label-uncontrolled-study-of-epoetin-zeta-on-the-treatment-of-chemotherapy-induced-anemia-in-solid-tumors
#14
Constantinos E Alifieris, Kyriakos Orfanakos, Aristina Papanota, George P Stathopoulos, Nikolaos Sitaras, Dimitrios T Trafalis
PURPOSE: This is a single-center uncontrolled retrospective study to evaluate the efficacy and safety of the biosimilar epoetin zeta after approval in chemotherapy-induced anemia (CIA). METHODS: Patients screened were >18 years old suffering from solid malignancies and CIA with Hg ≤10 or <11 g/dl if symptomatic anemia. Patients had measurable disease by TNM and Eastern Cooperative Oncology Group (ECOG). Patients were treated for at least 12 weeks and the primary endpoint was to determine the incidence of blood transfusions, and secondarily, the overall safety and efficacy defined as ≥1 g/dl rise in Hb concentration or ≥40,000 cells/μl rise in reticulocyte count...
April 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27956157/ibrutinib-for-patients-with-rituximab-refractory-waldenstr%C3%A3-m-s-macroglobulinaemia-innovate-an-open-label-substudy-of-an-international-multicentre-phase-3-trial
#15
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T Heffner, Chaim Shustik, Ramón García-Sanz, Robert F Cornell, Carlos Fernández de Larrea, Jorge J Castillo, Miquel Granell, Marie-Christine Kyrtsonis, Veronique Leblond, Argiris Symeonidis, Efstathios Kastritis, Priyanka Singh, Jianling Li, Thorsten Graef, Elizabeth Bilotti, Steven Treon, Christian Buske
BACKGROUND: In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease. METHODS: This multicentre, open-label substudy was done at 19 sites in seven countries in adults aged 18 years and older with confirmed Waldenström's macroglobulinaemia, refractory to rituximab and requiring treatment...
February 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27903235/erythropoietin-enhances-the-cytotoxic-effect-of-hydrogen-peroxide-on-colon-cancer-cells
#16
Anna Tankiewicz-Kwedlo, Justyna Magdalena Hermanowicz, Arkadiusz Surażyński, Wojciech Kwedlo, Dariusz Rożkiewicz, Krystyna Pawlak, Tomasz Domaniewski, Dariusz Pawlak
BACKGROUND: Cancer patients treated with alkylating agents and radiotherapy are exposed to high level of reactive oxygen species (ROS) in tissues. ROS can involve superoxide free radicals, peroxynitrite, singlet oxygen, nitric oxide and hydrogen peroxide. It is well documented that increased exposure to oxygen through a high metabolic rate could lead to a shortened life span. Ionizing radiation, use of drugs and the development of cancer can lead to cancer-induced anemia. Recombinant human erythropoietin (Epo) supplementation is one of the methods for treating anemia...
November 15, 2016: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/27882724/efficacy-and-safety-of-darbepoetin-alfa-initiated-at-hemoglobin-%C3%A2-10%C3%A2-g-dl-in-patients-with-stage-iv-cancer-and-chemotherapy-induced-anemia
#17
Ralph V Boccia, David H Henry, Laura Belton, Chet Bohac, Hassan H Ghazal
Data on efficacy and safety of darbepoetin alfa (DA) administered at hemoglobin (Hb) ≤10 g/dL are limited. In this analysis, we examined DA's efficacy and safety in patients with Stage IV cancers and chemotherapy-induced anemia (CIA) initiated on DA at Hb ≤10 g/dL. Data for patients with Stage IV cancers and CIA and who initiated DA at Hb ≤10 g/dL were extracted from three phase 3 trials identified in a central database of Amgen-sponsored DA studies in CIA. Efficacy outcomes were assessed by achievement of Hb increases of ≥1 g/dL and ≥2 g/dL and red blood cell (RBC) or whole blood transfusion requirements...
December 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27872759/impact-of-moderate-intensity-aerobic-exercise-on-chemotherapy-induced-anemia-in-elderly-women-with-breast-cancer-a-randomized-controlled-clinical-trial
#18
Heba M Mohamady, Hany F Elsisi, Yasser M Aneis
Exercises are often recommended for patients suffering from anemia to improve physical conditioning and hematologic parameters. Hence, the present study aimed to investigate the impact of moderate intensity aerobic exercise on chemotherapy-induced anemia. Thirty elderly women with breast cancer underwent chemotherapy and were randomly assigned into two equal groups; Group A received aerobic exercise for 25-40 min at 50-70% of the maximum heart rate, 3 times/week for 12 weeks in addition to usual daily living activities, medication and nutritional support...
January 2017: Journal of Advanced Research
https://www.readbyqxmd.com/read/27822071/biosimilar-epoetin-for-the-management-of-chemotherapy-induced-anemia-in-elderly-patients
#19
Jean-Emmanuel Kurtz, Pierre Soubeyran, Mauricette Michallet, Elisabeth Luporsi, Hélène Albrand
INTRODUCTION: Chemotherapy-induced anemia (CIA) is a frequent complication among cancer patients, with elderly patients more likely to suffer severe effects. Biosimilar erythropoiesis-stimulating agents lower costs of supportive cancer treatment, and thus are particularly relevant in the elderly cancer population, which is growing rapidly worldwide. The goal of this subanalysis was to compare the tolerability and effectiveness of an epoetin biosimilar for treating CIA in patients <70 years old vs patients ≥70 years old...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27773819/fancd2-protects-against-bone-marrow-injury-from-ferroptosis
#20
Xinxin Song, Yangchun Xie, Rui Kang, Wen Hou, Xiaofang Sun, Michael W Epperly, Joel S Greenberger, Daolin Tang
Bone marrow injury remains a serious concern in traditional cancer treatment. Ferroptosis is an iron- and oxidative-dependent form of regulated cell death that has become part of an emerging strategy for chemotherapy. However, the key regulator of ferroptosis in bone marrow injury remains unknown. Here, we show that Fanconi anemia complementation group D2 (FANCD2), a nuclear protein involved in DNA damage repair, protects against ferroptosis-mediated injury in bone marrow stromal cells (BMSCs). The classical ferroptosis inducer erastin remarkably increased the levels of monoubiquitinated FANCD2, which in turn limited DNA damage in BMSCs...
October 20, 2016: Biochemical and Biophysical Research Communications
keyword
keyword
51678
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"